Navigation Links
Transave Completes Enrollment in Arikace(TM) Phase II Bronchiectasis Study
Date:4/21/2009

Presently No Approved Treatments

MONMOUTH JUNCTION, N.J., April 21 /PRNewswire/ -- Transave, Inc., today reported completion of patient enrollment in a Phase II study evaluating the safety and efficacy of Arikace(TM) (liposomal amikacin for inhalation) in non-cystic fibrosis (CF) bronchiectasis patients. The results, which are expected to be available by mid-year, will shed new light on how this patient population responds to treatment. Presently, there are no approved treatments for the disease.

"Today's announcement marks the achievement of yet another important milestone in the development of Arikace for chronic lung infections," said Tim Whitten, Transave's Chief Executive Officer. "We believe Arikace has the potential to be an important new treatment for non-CF patients with bronchiectasis. We look forward to seeing the Phase II results in June and moving to Phase III as soon as possible."

The double-blind, placebo-controlled study is designed to evaluate Arikace in non-CF patients who have bronchiectasis with Pseudomonas lung infections. In the trial, 64 adult patients were randomized 2:1 to Arikace - either a 280 mg or a 560 mg dose - or placebo for 28 days, followed by a 28-day off-treatment observation period. Arikace and placebo are administered once daily using an Investigational eFlow(R) Nebulizer System (PARI Pharma GmbH), a novel, highly efficient, portable aerosol delivery system. Sixteen clinical sites throughout Europe and India are participating in the study.

Bronchiectasis is characterized by localized, irreversible enlargement of the bronchial tubes. Involved bronchi are dilated, inflamed, and easily collapsible, resulting in airflow obstruction and impaired clearance of secretions. The accumulation of mucus in the bronchi leads to frequent infections, which further reduce lung function in these patients. One of the m
'/>"/>

SOURCE Transave, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Eligard(R) six-month formulation successfully completes European approval procedure
2. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
3. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
4. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
5. GSI Securitization Completes Merger and Domicile Transfer
6. Medical Services International Inc. Completes Testing for European Union (EU) Application
7. Inverness Completes Acquisition of Cholestech
8. Billians HealthDATA Completes Comprehensive Long Term Care Database Update
9. Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants
10. Explorer completes the map ... for the bodys blueprint
11. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Reinberg HealthDay Reporter , WEDNESDAY, ... men with prostate cancer who also have certain heart problems ... a new study suggests. , , The therapy in question is ... to reduce levels of male hormones to prevent the growth ... current research, this hormone therapy was linked to triple the ...
(Date:10/30/2014)... Horse Sense & Sensitivity ... special needs individuals in the Jacksonville area, will be ... from 10-2:00 p.m. at Bailey's Farm (2202 Bishop Estates ... public and is designed to raise awareness and funds ... HSS Round-Up is free. Ticket purchases will be required ...
(Date:10/30/2014)... New York (PRWEB) October 30, 2014 ... Society (NAMS) came to a close on Saturday, ... meeting since the Society’s inception in 1989. NAMS is ... health and quality of life of all women during ... healthy aging. With over 2,000 physicians and thought leaders ...
(Date:10/30/2014)... Amy Norton HealthDay ... Exposure to a common plastics, chemical during pregnancy may have ... hints. Researchers found that baby boys born to moms ... have a shorter anogenital distance -- the space between the ... and it,s considered a marker of exposure to androgens ("male" ...
(Date:10/30/2014)... Oct. 29, 2014 (HealthDay News) -- A new vaccine ... meningococcal disease was approved by the U.S. Food and ... protect people between the ages of 10 and 25 ... serogroup B bacteria. The bacteria can infect ... spinal cord and brain. It is a leading cause ...
Breaking Medicine News(10 mins):Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 3Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 3Health News:FDA Approves New Vaccine to Protect Against Meningitis 2
... four randomized controlled trials that directly compared two different ... radiofrequency ablation (RFA) significantly improves patient survival compared to ... findings are in the February issue of Hepatology ... on behalf of the American Association for the Study ...
... women who should receive radiation after a mastectomy are ... new study from researchers at the University of ... women who were treated with a mastectomy for breast ... who fell clearly within guidelines recommending radiation treatment after ...
... one million families by offering an economic opportunity in ... Corporation Chairman and CEO Roger Barnett will launch a ... support to one million families in 2009. The ... "Families are struggling to make ends meet in ...
... WASHINGTON, Feb. 3 Green tea products have become ... shown evidence of its benefit against a variety of ... some components of green tea may counteract the anticancer ... be contraindicated for patients taking this medicine to ensure ...
... Feb. 3 America,s oldest voluntary health organization is ... Nolan. Elected National Board Chair, after more than a ... has successfully steered the American Lung Association to tackle ... emphasis of his chairmanship has been to build on ...
... to increased mortality, , , TUESDAY, Feb. 3 (HealthDay News) -- ... needs to be taken seriously, a new study concludes. , ... goes up for at least five years following any low-trauma ... fracture. , "All low-trauma fractures are associated with premature mortality, ...
Cached Medicine News:Health News:Radiofrequency treatment better than ethanol injection for small liver tumors 2Health News:U-M Study: 19% of Breast Cancer Patients Don't Receive Recommended Radiation After Mastectomy 2Health News:Shaklee Hits the Road With Its Infinite Possibilities Tour 2Health News:Green Tea May Negate the Effects of a Common Cancer Therapy 2Health News:Green Tea May Negate the Effects of a Common Cancer Therapy 3Health News:Green Tea May Negate the Effects of a Common Cancer Therapy 4Health News:Maryland Lawyer Steve Nolan Advocates for Lung Health as National Board Chair of the American Lung Association 2Health News:Fractures in Older Adults Up Death Risk 2
(Date:10/30/2014)... 2014 WuXi PharmaTech (Cayman) Inc. (NYSE: ... platform company serving the pharmaceutical, biotechnology, and medical device ... and the United States , today ... Tel Aviv area of Israel.  ... broad platform of integrated R&D services to local customers. ...
(Date:10/30/2014)...   ViaDerma, Inc. (OTCQB: VDRM), a ... to market, has recently released a revolutionary new ... topical liquid tetracycline-based antibiotic that uses a patent-pending ... medication active ingredients into topical drugs. The drug ... to help prevent skin infection in minor cuts, ...
(Date:10/30/2014)... , Oct. 30, 2014 Molecular Profiles Ltd., ... CBRX ) and Maryland -based Xceleron ... improved efficiency during clinical development that will be launched ... next week. This partnership extends Molecular Profiles, ... it launched earlier this month. The company also has ...
Breaking Medicine Technology:WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3
... prisms are of superior quality. Set of 16 includes 1/2, ... 35, 40, 45, and 50 diopter plus Red Lens. Each ... lbs)., , 4445xx , ,These prisms are of superior quality. ... 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, ...
Force 1C has a streamlined, compact design perfect for the requirements of outpatient surgery - as well as the power and performance features needed for a full range of general inpatient surgical pro...
... PC is the most powerful Isolated ESU on ... It is the only ESU that allows the ... field with a standard ES pencil. Excalibur Plus ... minimum necessary voltage for smooth cutting through various ...
Diamond phaco knife keratome shaped blade straight. 3.2 mm wide....
Medicine Products: